Market Cap 381.10B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 21.05
Forward PE 15.00
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 5,407,900
Avg Vol 6,736,016
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 74%
Beta 0.32
Analysts Strong Sell
Price Target $250.90

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Mike22332233
Mike22332233 May. 25 at 12:11 AM
$SLS $MRK $PFE $ABBV UPDATED HR VALUE ... THE GPS READOUT will be GAME-CHANGING FOR CANCER SURVIVAL!!! ... Using all the data that the REGAL Trial has put out on enrollment trenches and cohort data, the 66 death&toxicity report, the 60 event report, and the 72 event report, And, then using Monte Carlo simulations based on Cox proportional hazards to be used in the FDA final statistical analysis … My conclusions is: EFFECTIVELY, those getting GPS that had an immune response (80% of them), are NOT PASSING AWAY!!! ... When trial ends at the 80th event, we will find that NONE of the 63 BAT arm are still living … While 46 of the 63 GPS arm will still be alive !!!! … As I've said before: The HR Value will be 0.27 to 0.33 which is UNHEARD OF AND GROUNDBREAKING!!! … It’s A NEW STANDARD OF Care !!!! …. It’s A $40 Bil VALUATION !!! … It’s A BIG PHARMA BIDDING WAR FINAL BO VALUE OF $222 !!! ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 to get all updates
2 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 24 at 11:55 PM
$SLS $ABBV IDMC Unblinded KEY Median Overall Survival and Immune Response data from the Ongoing Phase 3 Interim Analysis - Since then SLS Market Value is up over 1,000%. why do you think that is? https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 24 at 10:18 PM
$SLS $ABBV do some due diligence on SLS before and after the IDMC Unblinded Select MOS and IR Data from the Phase 3 Interim Analysis - it told smart money GPS is Golden. https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 24 at 9:13 PM
$SLS $CING $RILY while we are seeing extended, mirculous all pooled survival in the SLS REGAL Phase 3 Trial - the BAT Best Available Treatment for Control ARM Patients recently Failed 3 Large Phase 3 Trials conducted by $ABBV. - it is not complicated. - IDMC Unblinded Actual MOS and IR data from the Interim Analysis: IR in 80% of Tested Gps Patients. IR is Directly Correlated with Survival in all prior Gps Trials - including 2 Phase 2's for AML Remission. 64% IR Rate in the AML CR2 GPS Phase 2, achieved a Stat Sig 21 Month MOS 64% IR = 21 Month MOS / 80% IR in the P3 = > 21 month MOS
2 · Reply
Mike22332233
Mike22332233 May. 24 at 8:03 PM
$SLS UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I uncover and post my Special Situation Stocks that have potential for HUGE & QUICK profits ahead ... which I always plow back into more $SLS !!!
1 · Reply
Mike22332233
Mike22332233 May. 24 at 7:39 PM
$SLS If you agree with what I will say, then LIKE this and FOLLOW me 👉 @Mike22332233 ... YES, I am VERY VERY BULLISH — I am playing this FOR A BUYOUT ONLY !! Based on research and what I know, this is my play: There is a 98+% chance the readout is positive and THEN I EXPECT 100% chance of a buyout at a MINIUM PRICE OF $50 to $75 (a $10 to $15 Billion valuation) and a MAXIMUM PRICE OF $150 to $175 (a $30 to $35 Billion valuation) within 3 months of the GPS Readout by one of the top 10 Big Pharma companies, most likely $MRK, $PFE or $ABBV ... There is a high chance that 2 or even 3 of these Big Pharma will get into a bidding war over buying $SLS, in which case my final Bidding War Buy Out price is $222 !!! … If you agree with what I will say, then LIKE this and FOLLOW me 👉 @Mike22332233 ...
2 · Reply
clan
clan May. 24 at 3:38 PM
$MNKD 🧱🏁🏎 Inhalable mealtime insulin. #Afrezza #inhalemyinsulin FAST IN! FAST OUT! $AMGN $ABBV $SNY
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 24 at 6:19 AM
$SLS $ABBV While We are Seeing Miraculous ALL POOLED Survival, BAT for Control Arm Pstients FAILED 3 AML Trials and GPS was Proven Effective at Preventing Relapse and Extending Survival in all 7 Prior trials, Including 2 Phase 2 Trials for AML Remission Maintenance. it is not complicated. "What is the Longest Survival you see in CR2 in your Practice?".
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 24 at 12:14 AM
$SLS $ABBV it is Not Complicated... BAT - for Control Arm Patients FAILED A PHASE 3 TRIAL For AML Patients in FIRST REMISSION. Aza+VEN Recently FAILED 3 Large Phase 3 Trials for AML Maintenance. VIALE-M Phase 3 for CR 1 Remission Maintenance FAILED VIALE-T Phase 3 for Post Transplant Maintenance FAILED VERONA MDS/HIGH RISK AML Maintenance FAILED BAT - also FAILED in the SLS PHASE 3 TRIAL for Second Remission Maintenance.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 23 at 7:27 PM
$SLS for all those interested in money. While we continue to see Miraculous ALL POOLED Survival Data, and wait for the 80th Event PR and ensuing Share Price Launch, Azacitidine +VEN the BAT - Best Available Treatment for the SLS Phase 3 CONTROL ARM Patients, Recently FAILED 3 Large Phase 3 Trials conducted by $ABBV. -- BAT FAILED the VIALE-M Trial for AML Patients in First Remission CR1 -- $ABBV Knows it Failed the SLS Phase 3 Second Remission CR2 Maintenance trial. The IDMC UNBLINDED ACTUAL MOS and IR DATA from the SLS Phase 3 INTERIM Analysis - Jan. Since then SLS Share PRICE/ Market Value/ Cash/ Institutional Investment is all + 10x .... SMART MONEY, SMARTER MONEY than the Retail Tools on ST Know - GPS is GOLDEN.
1 · Reply
Latest News on ABBV
AbbVie reports positive CHMP opinion for Maviret

2026-05-22T12:12:15.000Z - 2 days ago

AbbVie reports positive CHMP opinion for Maviret


AbbVie price target raised to $298 from $294 at Piper Sandler

2026-05-14T11:07:12.000Z - 10 days ago

AbbVie price target raised to $298 from $294 at Piper Sandler


AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 16 days ago

AbbVie Transcript: AGM 2026


AbbVie price target raised to $236 from $232 at Evercore ISI

2026-05-04T12:13:35.000Z - 20 days ago

AbbVie price target raised to $236 from $232 at Evercore ISI


AbbVie price target raised to $265 from $262 at Canaccord

2026-04-30T13:31:03.000Z - 24 days ago

AbbVie price target raised to $265 from $262 at Canaccord


AbbVie upgraded to Buy at BofA on durable growth

2026-04-30T10:15:57.000Z - 24 days ago

AbbVie upgraded to Buy at BofA on durable growth


AbbVie upgraded to Buy from Neutral at BofA

2026-04-30T10:14:18.000Z - 24 days ago

AbbVie upgraded to Buy from Neutral at BofA


AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

2026-04-29T16:39:58.000Z - 25 days ago

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74


AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 25 days ago

AbbVie Earnings Call Transcript: Q1 2026


AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 25 days ago

AbbVie Earnings release: Q1 2026


AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 25 days ago

AbbVie Quarterly report: Q1 2026


AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 25 days ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth


AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 25 days ago

AbbVie Reports First-Quarter 2026 Financial Results


US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 4 weeks ago

US FDA declines to approve AbbVie's wrinkle treatment


Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 14, 2026, 8:50 AM EDT - 5 weeks ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation


AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 31, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call


AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing


AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing


Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 9:26 AM EDT - 2 months ago

Buy Or Fear AbbVie Stock At $210?


AbbVie Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 11:20 AM EDT - 2 months ago

AbbVie Transcript: Leerink Global Healthcare Conference 2026


AbbVie Proxy statement: Proxy Filing

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy Filing


AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 11:10 AM EST - 2 months ago

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference


Mike22332233
Mike22332233 May. 25 at 12:11 AM
$SLS $MRK $PFE $ABBV UPDATED HR VALUE ... THE GPS READOUT will be GAME-CHANGING FOR CANCER SURVIVAL!!! ... Using all the data that the REGAL Trial has put out on enrollment trenches and cohort data, the 66 death&toxicity report, the 60 event report, and the 72 event report, And, then using Monte Carlo simulations based on Cox proportional hazards to be used in the FDA final statistical analysis … My conclusions is: EFFECTIVELY, those getting GPS that had an immune response (80% of them), are NOT PASSING AWAY!!! ... When trial ends at the 80th event, we will find that NONE of the 63 BAT arm are still living … While 46 of the 63 GPS arm will still be alive !!!! … As I've said before: The HR Value will be 0.27 to 0.33 which is UNHEARD OF AND GROUNDBREAKING!!! … It’s A NEW STANDARD OF Care !!!! …. It’s A $40 Bil VALUATION !!! … It’s A BIG PHARMA BIDDING WAR FINAL BO VALUE OF $222 !!! ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 to get all updates
2 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 24 at 11:55 PM
$SLS $ABBV IDMC Unblinded KEY Median Overall Survival and Immune Response data from the Ongoing Phase 3 Interim Analysis - Since then SLS Market Value is up over 1,000%. why do you think that is? https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 24 at 10:18 PM
$SLS $ABBV do some due diligence on SLS before and after the IDMC Unblinded Select MOS and IR Data from the Phase 3 Interim Analysis - it told smart money GPS is Golden. https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 24 at 9:13 PM
$SLS $CING $RILY while we are seeing extended, mirculous all pooled survival in the SLS REGAL Phase 3 Trial - the BAT Best Available Treatment for Control ARM Patients recently Failed 3 Large Phase 3 Trials conducted by $ABBV. - it is not complicated. - IDMC Unblinded Actual MOS and IR data from the Interim Analysis: IR in 80% of Tested Gps Patients. IR is Directly Correlated with Survival in all prior Gps Trials - including 2 Phase 2's for AML Remission. 64% IR Rate in the AML CR2 GPS Phase 2, achieved a Stat Sig 21 Month MOS 64% IR = 21 Month MOS / 80% IR in the P3 = > 21 month MOS
2 · Reply
Mike22332233
Mike22332233 May. 24 at 8:03 PM
$SLS UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I uncover and post my Special Situation Stocks that have potential for HUGE & QUICK profits ahead ... which I always plow back into more $SLS !!!
1 · Reply
Mike22332233
Mike22332233 May. 24 at 7:39 PM
$SLS If you agree with what I will say, then LIKE this and FOLLOW me 👉 @Mike22332233 ... YES, I am VERY VERY BULLISH — I am playing this FOR A BUYOUT ONLY !! Based on research and what I know, this is my play: There is a 98+% chance the readout is positive and THEN I EXPECT 100% chance of a buyout at a MINIUM PRICE OF $50 to $75 (a $10 to $15 Billion valuation) and a MAXIMUM PRICE OF $150 to $175 (a $30 to $35 Billion valuation) within 3 months of the GPS Readout by one of the top 10 Big Pharma companies, most likely $MRK, $PFE or $ABBV ... There is a high chance that 2 or even 3 of these Big Pharma will get into a bidding war over buying $SLS, in which case my final Bidding War Buy Out price is $222 !!! … If you agree with what I will say, then LIKE this and FOLLOW me 👉 @Mike22332233 ...
2 · Reply
clan
clan May. 24 at 3:38 PM
$MNKD 🧱🏁🏎 Inhalable mealtime insulin. #Afrezza #inhalemyinsulin FAST IN! FAST OUT! $AMGN $ABBV $SNY
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 24 at 6:19 AM
$SLS $ABBV While We are Seeing Miraculous ALL POOLED Survival, BAT for Control Arm Pstients FAILED 3 AML Trials and GPS was Proven Effective at Preventing Relapse and Extending Survival in all 7 Prior trials, Including 2 Phase 2 Trials for AML Remission Maintenance. it is not complicated. "What is the Longest Survival you see in CR2 in your Practice?".
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 24 at 12:14 AM
$SLS $ABBV it is Not Complicated... BAT - for Control Arm Patients FAILED A PHASE 3 TRIAL For AML Patients in FIRST REMISSION. Aza+VEN Recently FAILED 3 Large Phase 3 Trials for AML Maintenance. VIALE-M Phase 3 for CR 1 Remission Maintenance FAILED VIALE-T Phase 3 for Post Transplant Maintenance FAILED VERONA MDS/HIGH RISK AML Maintenance FAILED BAT - also FAILED in the SLS PHASE 3 TRIAL for Second Remission Maintenance.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 23 at 7:27 PM
$SLS for all those interested in money. While we continue to see Miraculous ALL POOLED Survival Data, and wait for the 80th Event PR and ensuing Share Price Launch, Azacitidine +VEN the BAT - Best Available Treatment for the SLS Phase 3 CONTROL ARM Patients, Recently FAILED 3 Large Phase 3 Trials conducted by $ABBV. -- BAT FAILED the VIALE-M Trial for AML Patients in First Remission CR1 -- $ABBV Knows it Failed the SLS Phase 3 Second Remission CR2 Maintenance trial. The IDMC UNBLINDED ACTUAL MOS and IR DATA from the SLS Phase 3 INTERIM Analysis - Jan. Since then SLS Share PRICE/ Market Value/ Cash/ Institutional Investment is all + 10x .... SMART MONEY, SMARTER MONEY than the Retail Tools on ST Know - GPS is GOLDEN.
1 · Reply
Blockwave1
Blockwave1 May. 23 at 2:28 PM
MASSIVE growth on Telegram 4,300+ members strong 🚀 The profits keep rolling in… no slowing down 🔥 Join the telegram channel:https://t.me/BlockWave10 ✅ $IBM 22 MAY 26 $240 CALL — 1,171% ✅ $HD 22 MAY 26 $415 CALL — 400% ✅ $IBM 29 MAY 26 $245 CALL — 400% ✅ $AAPL 22 MAY 26 $300 CALL — 263% ✅ $COST 22 MAY 26 $1,120 CALL — 203% ✅ $COST 22 MAY 26 $1,110 CALL — 201% ✅ $ABBV 22 MAY 26 $222.5 CALL — 156% THIS WEEK I dropped over 2,799%+ in FREE gains on STOCKTWITS 🔥
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 8:37 PM
$SLS $ABBV BAT IS NOT AN EFFECTIVE REMISSION MAINTENANCE TREATMENT
1 · Reply
Loudermilk64
Loudermilk64 May. 22 at 6:33 PM
$ABBV Pulling up.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 6:25 PM
$SLS the IDMC Unblinded Actual Phase 3 MOS and IR Data - ACTUAL MOS and IR DATA that Told Most Industry Players GPS is GOLDEN. $ABBV KNOWS Since the 60th Event - Dec 11th 2024/ Interim Analysis when the IDMC UNBLINDED ACTUAL PHASE 3 MOS and IR DATA in Jan 2025 - SLS Share Price Has increased 700%. - SLS Market Cap Has Increased 1,300% - SLS Cash on Hand has increased 1,400% to $110M / qburn of just $8M - Institutional Investors up to 167 over 50% from just 29 / 8% --- SMART MONEY KNOWS RIGHT NOW Gps is Golden protip: ask your favorite lying short scumbag, why Control ARM BAT / AzaVEN FAILED 3 Large Phase 3 Trials???
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 6:13 PM
$SLS 60th Event Launched the Share Price - Because the IDMC Unblinded Actual Phase 3 MOS and IR Data - ACTUAL MOS and IR DATA that Told Most Industry Players GPS is GOLDEN. $ABBV KNOWS. - The 72nd Event PR ALSO Launched the Share Price - The 78th Event PR ALSO Launched the Share Price • the Imminent 80th and FINAL Event PR - will Absolutely Send this - stratospheric - BALLISTIC VERTICALITY. • 80th Event PR is coming. It is Imminent and Inevitable. - 26 + months ranging up to 64 months, Events are NOT LINEAR. Easily could see a rapid spate of 2 or 3 Events in a given month. The Registrational Phase 3 Results will Give Gps the FDA Green light to treat Upwards of 50,000 AML Remission Patients each year + another 100,000 Right Now Currently IN REMISSION who'll Immediately benefit from Gps Immunotherapy. $28B + Total Addressable Market. This Puny $1.47B Mcap is instantly worth $40B + the moment the Market Sees the Pha 3 Results. - $ABVX from $5 / $270M Mcap to $148 / $12.5B
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 6:00 PM
$SLS $LLY $ABBV For anyone interested in Real Numbers / attempting to Quantify the TRUE Value of Gps Immunotherapy • Gps CR2/3 Market 12,500 Patients Per year • average 3 year Dosing Regime • $280K Year 1 $110K Year 2 $70K Year 3 -- just this initial CR2/3 Market Segment alone is worth $75 Per Share. protip: GPS Phase 3 MOS is already known to be Greater than the P2 MOS and based on current followup - GPS P3 MOS is Not Yet MET and >30.5 months. - this 3x 4x OS Advantage for CR2/3 Patients Requires the Market Ascribe Value to GPS for CR1 patients as well.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 5:52 PM
$SLS for the Short Lowlife Getting conned by other Short Lowlife - AZA+VEN - THE BAT - Best Available Treatment, for Control ARM Patients. - RECENTLY FAILED - 3 LARGE PHASE 3 TRIALS CONDUCTED BY $ABBV - Including Failing the VIALE-M Trial for AML REMISSION MAINTENANCE. VIALE-M FAILED a First Remission P3 Trial due to Toxicity VIALE-T FAILED a Post Transplant Maintenance P3 again due to Toxicity - it is not Effective in Maintaining Remission. Meanwhile GPS was Proven Effective at Preventing Relapse and Extending Survival in ALL Prior trials, Including 2 Phase 2 Trials for AML Remission Maintenance.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 5:44 PM
$SLS While we continue to See near miraculous ALL POOLED - BLINDED Survival, BAT for Control ARM Patients - Recently FAILED 3 Large Phase 3 Trials - BAT for Phase 3 Control ARM Patients FAILED 3 large randomized, different Dosing Arms, Oral, IV, 3 expensive P3 trials conducted by $ABBV - 2 of which VIALE-M VIALE-T were in AML REMISSION. - GPS was Proven Effective at Preventing Relapse and Extending Survival in all 7 Prior trials, Including 2 Phase 2 Trials for AML Remission Maintenance. It is Not Complicated. \ Be HOLDING when the 80th Event is announced.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 5:22 PM
$SLS $ABBV While We are Seeing Miraculous ALL POOLED Survival, BAT FAILED 3 AML Trials and GPS was Proven Effective at Preventing Relapse and Extending Survival in all 7 Prior trials, Including 2 Phase 2 Trials for AML Remission Maintenance. it is not complicated. "What is the Longest Survival you see in CR2 in your Practice?".
0 · Reply
Loudermilk64
Loudermilk64 May. 22 at 5:14 PM
$ABBV I hope that 200 day can hold support.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 4:43 PM
$SLS 60th Event Launched the Share Price - Because the IDMC Unblinded Actual Phase 3 MOS and IR Data - ACTUAL MOS and IR DATA that Told Most Industry Players GPS is GOLDEN. $ABBV KNOWS. - The 72nd Event PR ALSO Launched the Share Price - The 78th Event PR ALSO Launched the Share Price • the Imminent 80th and FINAL Event PR - will Absolutely Send this - stratospheric - BALLISTIC VERTICALITY. • 80th Event PR is coming. It is Imminent and Inevitable. - 26 + months ranging up to 64 months, Events are NOT LINEAR. Easily could see a rapid spate of 2 or 3 Events in a given month. The Registrational Phase 3 Results will Give Gps the FDA Green light to treat Upwards of 50,000 AML Remission Patients each year + another 100,000 Right Now Currently IN REMISSION who'll Immediately benefit from Gps Immunotherapy. $28B + Total Addressable Market. This Puny $1.47B Mcap is instantly worth $40B + the moment the Market Sees the Pha 3 Results. - $ABVX from $5 / $270M Mcap to $148 / $12.5B
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 22 at 4:26 PM
$SLS Most of real Investors here already know, but for the Short Lowlife Getting conned - AZA+VEN - THE BAT - Best Available Treatment, for Control ARM Patients. - RECENTLY FAILED - 3 LARGE PHASE 3 TRIALS CONDUCTED BY $ABBV - Including Failing the VIALE-M Trial for AML REMISSION MAINTENANCE. VIALE-M FAILED a First Remission P3 due to Toxicity VIALE-T FAILED a Post Transplant Maintenance P3 again due to Toxicity - it is not Effective in Maintaining Remission. GPS was Proven Effective at Preventing Relapse and Extending Survival in all 7 Prior trials, Including 2 Phase 2 Trials for AML Remission Maintenance.
2 · Reply